Key result
Sisunatovir proves safe and well tolerated in children with RSV-LRTI with no treatment-related serious AEs.
Why the study?
Sisunatovir is an investigational RSV antiviral shown to be effective in an adult human viral challenge study, but its safety and pharmacokinetics required evaluation in pediatric populations.
Does sisunatovir demonstrate safety and adequate pharmacokinetics in infants and children with RSV lower respiratory tract infection?
RCT (n=60)
Yes
Does sisunatovir demonstrate safety and adequate pharmacokinetics in infants and children with RSV lower respiratory tract infection?
Sisunatovir is safe, well-tolerated, and achieves target plasma concentrations in infants and children with RSV lower respiratory tract infection.
Answers are grounded in this paper and cite their sources.
Supports progression to efficacy trials in pediatric RSV; extends adult data to infants and young children.
Background: Sisunatovir is an investigational respiratory syncytial virus (RSV) antiviral that was effective in an adult human viral challenge study. Methods: In 2 multicenter studies, safety and pharmacokinetics of sisunatovir were evaluated in hospitalized individuals 1 month to 36 months of age (Study 1) and outpatient and hospitalized individuals 1 day to 60 months of age (Study 2) with RSV lower respiratory tract infection (RSV-LRTI). In Study 1 Part A, participants received single sisunatovir doses; in Part B, participants received placebo or multiple ascending sisunatovir doses every 12 hours for 5 days. In Study 2, participants received weight-based sisunatovir dosing or placebo every 12 hours for 5 days. Results: In Study 1 Part A, 19 participants received sisunatovir; 31 in Part B received sisunatovir (n = 22) or placebo (n = 9). Adverse events (AEs) were reported by 11 (57.9%) and 12 (38.7%) participants in Parts A and B, respectively. In Study 2, 10 participants received sisunatovir (n = 6) or placebo (n = 4). No treatment-related serious AEs were reported; all AEs were mild or moderate. In Study 1 Part A 12 hours post-dose, mean sisunatovir concentrations were within safety margins. In Part B, at the highest dose assessed for each group, steady-state trough concentrations surpassed those effective in the adult challenge study. Conclusions: In children with RSV-LRTI, sisunatovir was safe and well tolerated. The pediatric multiple-dose regimen achieved plasma concentrations effective at reducing viral load and symptoms in an adult challenge study; however, further studies are needed to identify doses providing comparable exposure across pediatric populations. ClinicalTrials.gov registration number: NCT04225897 (registered December 11, 2019); NCT06102174 (registered October 6, 2023)
No takes yet. Share an insight, caveat, or question.
Toussi et al. (2026) conducted an RCT in RSV lower respiratory tract infection (RSV-LRTI) (n=60). Sisunatovir vs. Placebo was evaluated on Safety (adverse events) and pharmacokinetics. Sisunatovir was safe and well tolerated in children with RSV-LRTI, with adverse events reported in 57.9% of single-dose and 38.7% of multiple-dose participants, and no treatment-related serious AEs.
Synapse has enriched 10 related papers. Consider them for comparative context: